Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
When treatment for ulcerative colitis with steroids and immunosuppressants is ineffective or poorly tolerated, two placebo-controlled trials have demonstrated that infliximab yields remissions permitting steroid withdrawal in about 20% of patients. However, the long-term risks of infections and cancer mean that infliximab should be reserved for the most severely ill patients.